JP5663699B2 - ピラゾール誘導体及びその医薬用途 - Google Patents

ピラゾール誘導体及びその医薬用途 Download PDF

Info

Publication number
JP5663699B2
JP5663699B2 JP2014514708A JP2014514708A JP5663699B2 JP 5663699 B2 JP5663699 B2 JP 5663699B2 JP 2014514708 A JP2014514708 A JP 2014514708A JP 2014514708 A JP2014514708 A JP 2014514708A JP 5663699 B2 JP5663699 B2 JP 5663699B2
Authority
JP
Japan
Prior art keywords
constipation
day
compound
administration
stool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014514708A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013168671A1 (ja
Inventor
伊佐治 正幸
正幸 伊佐治
理明 竹村
理明 竹村
英俊 伊澤
英俊 伊澤
之彦 布袋
之彦 布袋
格 宮下
格 宮下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Priority to JP2014514708A priority Critical patent/JP5663699B2/ja
Application granted granted Critical
Publication of JP5663699B2 publication Critical patent/JP5663699B2/ja
Publication of JPWO2013168671A1 publication Critical patent/JPWO2013168671A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014514708A 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途 Active JP5663699B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014514708A JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012105847 2012-05-07
JP2014514708A JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014245645A Division JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
JP5663699B2 true JP5663699B2 (ja) 2015-02-04
JPWO2013168671A1 JPWO2013168671A1 (ja) 2016-01-07

Family

ID=49550709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014514708A Active JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途
JP2014245645A Active JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014245645A Active JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Country Status (15)

Country Link
US (2) US9273085B2 (OSRAM)
EP (1) EP2848254B1 (OSRAM)
JP (2) JP5663699B2 (OSRAM)
KR (1) KR101868991B1 (OSRAM)
CN (1) CN104284665B (OSRAM)
AU (1) AU2013258566B2 (OSRAM)
BR (1) BR112014027841B1 (OSRAM)
CA (1) CA2872002C (OSRAM)
DK (1) DK2848254T3 (OSRAM)
ES (1) ES2601127T3 (OSRAM)
MX (1) MX359988B (OSRAM)
PL (1) PL2848254T3 (OSRAM)
PT (1) PT2848254T (OSRAM)
RU (1) RU2602739C2 (OSRAM)
WO (1) WO2013168671A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2637668T (lt) 2010-11-04 2016-09-12 Albireo Ab Ibat inhibitoriai kepenų ligoms gydyti
JP5663699B2 (ja) * 2012-05-07 2015-02-04 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途
ES2694110T3 (es) 2013-02-04 2018-12-18 Taisho Pharmaceutical Co., Ltd. Fármaco profiláctico o terapéutico para el estreñimiento
KR102296314B1 (ko) * 2014-06-25 2021-09-01 이에이 파마 가부시키가이샤 고형 제제 및 그의 안정화 방법
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
WO2019191352A1 (en) 2018-03-28 2019-10-03 Avolynt Method for treating post-prandial hypoglycemia
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
MY209425A (en) 2018-06-20 2025-07-08 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
HRP20230039T1 (hr) 2019-02-06 2023-06-09 Albireo Ab Benzotiadiazepinski spojevi i njihova uporaba kao modulatora žučnih kiselina
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の1/2フマル酸塩

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
JPWO2011002001A1 (ja) * 2009-07-01 2012-12-13 キッセイ薬品工業株式会社 ピラゾール誘導体とビグアナイド薬との組み合わせ医薬
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP5663699B2 (ja) * 2012-05-07 2015-02-04 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の1/2フマル酸塩

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014047874; Diabetes Journal Vol.31, No.3, 2003, p.86-91 *
JPN6014047875; モダンフィジシャン Vol.18, No.6, 1998, p.717-719 *

Also Published As

Publication number Publication date
RU2014149181A (ru) 2016-06-27
BR112014027841A8 (pt) 2021-09-28
JP6105546B2 (ja) 2017-03-29
PL2848254T3 (pl) 2017-03-31
KR20150013671A (ko) 2015-02-05
MX2014013696A (es) 2015-02-05
PT2848254T (pt) 2016-10-05
RU2602739C2 (ru) 2016-11-20
EP2848254A4 (en) 2015-07-15
KR101868991B1 (ko) 2018-06-19
JP2015083580A (ja) 2015-04-30
EP2848254A1 (en) 2015-03-18
US9273085B2 (en) 2016-03-01
DK2848254T3 (en) 2016-10-31
WO2013168671A1 (ja) 2013-11-14
ES2601127T3 (es) 2017-02-14
MX359988B (es) 2018-10-18
HK1204773A1 (en) 2015-12-04
AU2013258566B2 (en) 2017-03-16
JPWO2013168671A1 (ja) 2016-01-07
US20160129031A1 (en) 2016-05-12
US9694027B2 (en) 2017-07-04
BR112014027841A2 (pt) 2017-06-27
BR112014027841B1 (pt) 2022-08-09
AU2013258566A1 (en) 2014-11-27
CN104284665A (zh) 2015-01-14
CA2872002A1 (en) 2013-11-14
CA2872002C (en) 2019-01-15
US20150141631A1 (en) 2015-05-21
EP2848254B1 (en) 2016-08-03
CN104284665B (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
JP5663699B2 (ja) ピラゾール誘導体及びその医薬用途
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
JP6448001B2 (ja) 液体配合剤
CN103338768A (zh) 胃和结肠的配制剂及其制备和使用方法
JP6473254B2 (ja) 下痢を治療するための製品及び方法
KR20240043778A (ko) 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
KR20200017487A (ko) 비알코올성 지방간염 치료를 위한 리코플리고진
TW202410887A (zh) 用於治療肌肉萎縮性脊髓側索硬化症之方法及組成物
JP6454436B1 (ja) ペマフィブラートを含有する医薬
CN116887822A (zh) 治疗软骨发育不全的方法
CN106456620A (zh) 胃轻瘫用5‑ht4受体激动剂
HK1204773B (en) Pyrazole derivative and use thereof for medical purposes
TWI659739B (zh) 便秘症之預防或治療藥
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
Hanson It’s Not the End: What’s New in Ileal Impactions
US20110269792A1 (en) Compositions useful for treating irritable bowel syndrome

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141208

R150 Certificate of patent or registration of utility model

Ref document number: 5663699

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250